[Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].

作者：Y Q Wang, Li Shen, Juefeng Wan, Hailin Zhang, Yu Wang, Xiaohua Wu, J W Wang, Ruimin Wang, Yuxiang Sun, Ting Tong, Dan Huang, Liang Wang, Weiqi Sheng, Xiang Zhang, Guoxiang Cai, Ye Xu, Sanjun Cai, Zihan Zhang, F Xia · 发表于：PubMed · 年份：2023 · DOI：10.3760/cma.j.cn441530-20230107-00010 · 被引用次数：13 · 研究领域：Colorectal Cancer Surgical Treatments、Colorectal Cancer Treatments and Studies、Colorectal and Anal Carcinomas

SCRT-based total neoadjuvant therapy combined with toripalimab can achieve a surprisingly good CR rate in patients with LARC and thus has the potential to offer new treatment options for organ preservation in patients with MSS and lower-location rectal cancer. Meanwhile, the preliminary findings of a single center show good tolerability, the main Grade III-IV AE being thrombocytopenia. The significant efficacy and long-term prognostic benefit need to be determined by further follow-up.